Screener
Prime Medicine PRME Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows provided by financing activities: | ||
| Net proceeds from stock option exercises | 416 | — |
| Proceeds from ESPP offerings | 338 | 197 |
| Proceeds from research and development funding liability | — | 6,000 |
| Net cash provided by financing activities | 754 | 6,197 |
| Net change in cash, cash equivalents, and restricted cash | (15,581) | (129,043) |
| Cash, cash equivalents, and restricted cash at beginning of period | 76,723 | 196,538 |
| Cash, cash equivalents, and restricted cash at end of period | $61,142 | $67,495 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's financing cash flow?
- Prime Medicine (PRME) reported financing cash flow of $361K in Q2 2026.
- How has Prime Medicine's financing cash flow changed year-over-year?
- Prime Medicine's financing cash flow increased by 83.2% year-over-year, from $197K to $361K.
- What is the long-term trend for Prime Medicine's financing cash flow?
- Over 4 years (2021 to 2025), Prime Medicine's financing cash flow has grown at a -13.4% compound annual growth rate (CAGR), from $269.28M to $151.51M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Prime Medicine's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude